Corcept (NASDAQ: CORT) executive reports stock grants and tax withholding moves
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Corcept Therapeutics executive Sean Maduck reported equity award activity and related tax withholding. On March 2, 2026, he acquired two grants of common stock totaling 908 shares, including 454 purchase-plan shares priced under a company purchase plan and 454 shares granted at no cost as an award. On March 3, 2026, 110 shares were withheld by Corcept at a price of $35.97 per share to cover tax obligations tied to vesting restricted stock units, leaving 8,977 common shares held directly.
The filing also lists indirect ownership stakes through several entities, including the Sean and Molly Maduck Living Trust, MMM 2025, LLC, two SNM Grantor Retained Annuity Trusts, and Duckhill Capital, LLC. Maduck disclaims beneficial ownership of Duckhill Capital, LLC shares beyond his pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Maduck Sean
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 110 | $35.97 | $4K |
| Grant/Award | Common Stock | 454 | $35.97 | $16K |
| Grant/Award | Common Stock | 454 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 8,977 shares (Direct);
Common Stock — 5,147 shares (Indirect, See Footnote)
Footnotes (1)
- The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Includes 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025, 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. The closing price on March 2, 2026 was used to calculate the withholding obligation. Includes 888 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025, 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025 and 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee. Represents the shares held by MMM 2025, LLC of which the Reporting Person is a member and manager. Represents the shares held by SNM 2025 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. Represents the shares held by SNM 2026 Grantor Retained Annuity Trust of which the Reporting Person is the trustee. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
FAQ
What insider transactions did Sean Maduck report in Corcept Therapeutics (CORT) stock?
Sean Maduck reported equity awards and tax withholding in Corcept common stock. He received two stock grants totaling 908 shares on March 2, 2026, and 110 shares were withheld on March 3, 2026 to satisfy tax obligations tied to vesting restricted stock units.
Did the Corcept (CORT) Form 4 show an open-market stock sale by Sean Maduck?
The Form 4 does not show an open-market sale by Sean Maduck. Instead, 110 shares were withheld by Corcept at $35.97 per share to cover tax withholding on vesting restricted stock units, a common administrative disposition rather than a discretionary market sale.
What are the terms of Sean Maduck’s unvested Corcept (CORT) restricted stock awards?
Unvested awards include blocks of 266, 888, 228, and 205 shares granted in 2025, plus awards under the 2024 Purchase Plan. For each grant, 100% of the underlying shares vest on the one-year grant anniversary if he meets specified continued-service or ownership conditions.